Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella

[1]  B. Hrafnkelsson,et al.  The impact and cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the paediatric immunisation programme in Iceland—A population-based time series analysis , 2021, PloS one.

[2]  M. Jit,et al.  Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore. , 2021, Vaccine.

[3]  M. Nygård,et al.  Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysis. , 2021, Preventive medicine.

[4]  D. Caugant,et al.  Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine , 2021, Human vaccines & immunotherapeutics.

[5]  Scott Williams,et al.  Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia , 2021, Infectious Diseases and Therapy.

[6]  M. Postma,et al.  Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review , 2021, Vaccines.

[7]  E. Elbasha,et al.  Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study , 2021, BMC Infectious Diseases.

[8]  M. Postma,et al.  Rotavirus Vaccination of Infants Delayed and Limited within the National Immunization Programme in the Netherlands: An Opportunity Lost , 2020, Vaccines.

[9]  E. Beck,et al.  Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  E. Mayo-Wilson,et al.  PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews , 2020, BMJ.

[11]  E. Elbasha,et al.  Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France. , 2020, Vaccine.

[12]  S. McGhee,et al.  Economic evaluation of the introduction of rotavirus vaccine in Hong Kong. , 2020, Vaccine.

[13]  E. I. H. Akpo,et al.  Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Luyten,et al.  Value Frameworks for Vaccines: Which Dimensions Are Most Relevant? , 2020, Vaccines.

[15]  D. Ekwueme,et al.  Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model. , 2020, Vaccine.

[16]  D. Hutton,et al.  Epidemiological impact and cost-effectiveness of universal meningitis b vaccination among college students prior to college entry , 2020, PloS one.

[17]  N. Chiu,et al.  Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan , 2020, Cost Effectiveness and Resource Allocation.

[18]  M. Postma,et al.  Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands. , 2020, Vaccine.

[19]  H. Sings,et al.  Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective Analysis , 2020, Infectious Diseases and Therapy.

[20]  J. Laine,et al.  Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis , 2020, Infectious Diseases and Therapy.

[21]  P. Bonanni,et al.  Assessment of the Clinical and Economic Impact of Different Immunization Protocols of Measles, Mumps, Rubella and Varicella in Internationally Adopted Children , 2020, Vaccines.

[22]  F. Ansaldi,et al.  Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy , 2020, Pathogens.

[23]  S. Snedecor,et al.  Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada , 2020, Canadian Journal of Public Health.

[24]  B. Standaert,et al.  Estimating the money flow in the economy attributed to rotavirus disease and vaccination in the Netherlands using a Social Accounting Matrix (SAM) framework , 2019, Expert review of pharmacoeconomics & outcomes research.

[25]  J. Dunn,et al.  The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia , 2019, PloS one.

[26]  D. Liew,et al.  Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents. , 2019, Vaccine.

[27]  D. S. Kim,et al.  Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study. , 2019, Vaccine.

[28]  M. Keeling,et al.  Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK , 2019, BMC Infectious Diseases.

[29]  R. Watts,et al.  Use of Checklists in Reviews of Health Economic Evaluations, 2010 to 2018. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[30]  M. San Martin,et al.  Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain , 2019, Human vaccines & immunotherapeutics.

[31]  I. Leeds,et al.  Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults. , 2019, American journal of preventive medicine.

[32]  M. Elsobky,et al.  A Comparison of Pneumococcal Vaccination Strategies and the Estimated Public Health and Economic Impact in Kuwait , 2019, Journal of Infection and Public Health.

[33]  A. Cripps,et al.  Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. , 2018, Vaccine.

[34]  M. Postma,et al.  Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium , 2018, Infectious Diseases and Therapy.

[35]  M. Gualano,et al.  Cost-effectiveness estimates of vaccination against rotavirus in Piedmont, Italy. , 2018, Journal of infection and public health.

[36]  H. D. de Melker,et al.  Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting , 2018, BMC Medicine.

[37]  K. Tsui,et al.  Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis , 2018, BMC Medicine.

[38]  P. Sparén,et al.  Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. , 2018, Vaccine.

[39]  B. Lee,et al.  Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore. , 2018, Singapore medical journal.

[40]  M. Postma,et al.  Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada , 2018, Infectious Diseases and Therapy.

[41]  A. Casuccio,et al.  Universal rotavirus vaccination program in Sicily: Reduction in health burden and cost despite low vaccination coverage , 2018, Human vaccines & immunotherapeutics.

[42]  L. Varghese,et al.  A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand , 2018, Applied Health Economics and Health Policy.

[43]  M. Sturkenboom,et al.  Methodology for computing the burden of disease of adverse events following immunization , 2018, Pharmacoepidemiology and drug safety.

[44]  A. Pavelyev,et al.  Clinical and economic impact of school‐based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis , 2018, BJOG : an international journal of obstetrics and gynaecology.

[45]  O. Leeuwenkamp,et al.  Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea , 2017, Human vaccines & immunotherapeutics.

[46]  G. Liguori,et al.  Impact of 13valent vaccine for prevention of pneumococcal diseases in children and adults at risk: possible sceneries in Campania region. , 2018, Infectious disorders drug targets.

[47]  A. P. Ortiz,et al.  Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico , 2017, PloS one.

[48]  A. Uusküla,et al.  Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage. , 2017, Vaccine.

[49]  J. Ollgren,et al.  Impact of five years of rotavirus vaccination in Finland - And the associated cost savings in secondary healthcare. , 2017, Vaccine.

[50]  M. Postma,et al.  Inclusion Of Safety/ADR-Related Outcomes In Economic Evaluations For Seasonal Influenza Vaccines: A Review Of Available Studies , 2017 .

[51]  M. Gambhir,et al.  Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effective. , 2017, Vaccine.

[52]  R. Mikolajczyk,et al.  Cost-effectiveness of human papillomavirus vaccination in Germany , 2017, Cost Effectiveness and Resource Allocation.

[53]  B. Standaert,et al.  Economic assessment of rotavirus vaccination in Saudi Arabia. , 2017, Journal of infection and public health.

[54]  E. Flem,et al.  Re–evaluation of the cost–effectiveness and effects of childhood rotavirus vaccination in Norway , 2017, PloS one.

[55]  J. Berkhof,et al.  Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands , 2017, The Journal of infectious diseases.

[56]  G. Palù,et al.  Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy , 2017, Human vaccines & immunotherapeutics.

[57]  G. Baio,et al.  Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy , 2017, Cost Effectiveness and Resource Allocation.

[58]  R. Hutubessy,et al.  Global economic evaluations of rotavirus vaccines: A systematic review. , 2017, Vaccine.

[59]  T. Delea,et al.  Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada , 2017, PloS one.

[60]  S. Tay,et al.  The clinical and economic benefits of school‐based quadrivalent HPV vaccination in Singapore , 2017, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[61]  I. Okubo,et al.  Economic evaluation of routine infant rotavirus immunisation program in Japan , 2017, Human vaccines & immunotherapeutics.

[62]  K. Atkins,et al.  Impact of the national rotavirus vaccination programme on acute gastroenteritis in England and associated costs averted , 2017, Vaccine.

[63]  C. Trotter,et al.  Modelling the cost-effectiveness of catch-up ‘MenB’ (Bexsero) vaccination in England , 2017, Vaccine.

[64]  P. Beutels,et al.  Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia. , 2017, Vaccine.

[65]  K. Petry,et al.  An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany , 2017, Expert review of pharmacoeconomics & outcomes research.

[66]  J. M. Schulenburg,et al.  Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany , 2017, The European Journal of Health Economics.

[67]  L. Stanberry,et al.  Vaccine safety evaluation: Practical aspects in assessing benefits and risks. , 2016, Vaccine.

[68]  M. Postma,et al.  Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16/18-positive cervical intraepithelial neoplasia in the Netherlands. , 2016, Vaccine.

[69]  M. Postma,et al.  Inclusion Of Costs And Effects Related To Toxicity/Safety In Cost -Effectiveness Analysis; An Illustration For Influenza Vaccines , 2016 .

[70]  O. Leeuwenkamp,et al.  Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model , 2016, BMJ Open.

[71]  M. Brisson,et al.  Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. , 2016, The Journal of infectious diseases.

[72]  A. Galvani,et al.  Cost-Effectiveness of Rotavirus Vaccination in France-Accounting for Indirect Protection. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[73]  O. Wichmann,et al.  Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany. , 2016, Vaccine.

[74]  M. Brisson,et al.  Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine. , 2016, The Journal of infectious diseases.

[75]  E. Tànfani,et al.  Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis , 2016, Human vaccines & immunotherapeutics.

[76]  B. Dervaux,et al.  Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. , 2016, Vaccine.

[77]  C. Stein-Zamir,et al.  Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel , 2016, International Journal of Public Health.

[78]  C. Bauch,et al.  National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States , 2016, Proceedings of the National Academy of Sciences.

[79]  E. Joura,et al.  Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria , 2016, BMC Infectious Diseases.

[80]  B. Sander,et al.  The cost-utility of integrated cervical cancer prevention strategies in the Ontario setting - Can we do better? , 2016, Vaccine.

[81]  D. Ekwueme,et al.  The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model , 2016, Human vaccines & immunotherapeutics.

[82]  V. Lee,et al.  Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong , 2016, Human vaccines & immunotherapeutics.

[83]  P. Beutels,et al.  Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical. , 2016, Vaccine.

[84]  M. Boily,et al.  Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. , 2016, Journal of the National Cancer Institute.

[85]  G. Baio,et al.  Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[86]  D. Ekwueme,et al.  O16.4 The estimated impact and cost-effectiveness of nonavalent hpv vaccination in the united states , 2015 .

[87]  A. Chuck,et al.  Value Added by the Prevnar 13 Childhood Immunization Program in Alberta, Canada (2010–2015) , 2015, Drugs - Real World Outcomes.

[88]  M. Connolly,et al.  Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework , 2015, Health Economics Review.

[89]  H. Starkie Camejo,et al.  Does it matter? Discounting and its role in the cost-effectiveness of preventative interventions. The case of HPV vaccination. , 2015, Public health.

[90]  S. Venturelli,et al.  A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer , 2015, Journal of Family Planning and Reproductive Health Care.

[91]  Wanrudee Isaranuwatchai,et al.  A cost‐effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer , 2015, Cancer.

[92]  A. Clark,et al.  Cost-effectiveness of pneumococcal conjugate vaccination in Croatia. , 2015, Vaccine.

[93]  A. Melegaro,et al.  Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme , 2015, PloS one.

[94]  M. Ouwens,et al.  Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster. , 2015, Clinical therapeutics.

[95]  J. Olsen,et al.  Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females , 2015, Cost Effectiveness and Resource Allocation.

[96]  H. Chesson,et al.  The cost-effectiveness of human papillomavirus vaccine catch-up programs for women. , 2015, The Journal of infectious diseases.

[97]  M. Jit,et al.  Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model , 2015, BMJ : British Medical Journal.

[98]  M. Nygård,et al.  Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway. , 2014, The Journal of infectious diseases.

[99]  T. Mrkvan,et al.  Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children , 2014, Infectious Diseases and Therapy.

[100]  N. Demarteau,et al.  Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model , 2014, BMC Public Health.

[101]  S. Regnier,et al.  Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: Results from a decision-analysis model , 2014, Human vaccines & immunotherapeutics.

[102]  W. Edmunds,et al.  Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study , 2014, BMJ : British Medical Journal.

[103]  M. Jit,et al.  Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. , 2014, Vaccine.

[104]  A. Karmann,et al.  Recommendation of rotavirus vaccination and herd effect: a budget impact analysis based on German health insurance data , 2014, The European Journal of Health Economics.

[105]  T. Blakely,et al.  Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program , 2014, BMC Infectious Diseases.

[106]  M. O'Brien,et al.  Cost effectiveness of a pentavalent rotavirus vaccine in Oman , 2014, BMC Infectious Diseases.

[107]  M. Postma,et al.  A few years later , 2014, Human vaccines & immunotherapeutics.

[108]  T. Blakely,et al.  Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand. , 2014, Vaccine.

[109]  M. Boily,et al.  Potential cost‐effectiveness of the nonavalent human papillomavirus (HPV) vaccine , 2014, International journal of cancer.

[110]  O. Wichmann,et al.  Cost-effectiveness of childhood rotavirus vaccination in Germany. , 2014, Vaccine.

[111]  I. Imaz,et al.  Budget impact and cost-utility analysis of universal infant rotavirus vaccination in Spain. , 2014, Preventive medicine.

[112]  L. Wang,et al.  Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009 , 2014, Pediatrics.

[113]  M. Nygård,et al.  Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys , 2014, PloS one.

[114]  E. Joura,et al.  Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost–effectiveness analysis , 2014, Expert review of pharmacoeconomics & outcomes research.

[115]  B. Sander,et al.  Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. , 2014, Vaccine.

[116]  Sun-Young Kim,et al.  Cost-Effectiveness Analyses of Vaccination Programmes , 2012, PharmacoEconomics.

[117]  M. Verweij,et al.  Criteria for inclusion of vaccinations in public programmes. , 2010, Vaccine.

[118]  R F Nease,et al.  Parents' preferences for outcomes associated with childhood vaccinations , 2000, The Pediatric infectious disease journal.